Time to reconsider urate: Neuroprotective potential may prevail on cardiovascular risk in animal models and clinical trials

EBioMedicine. 2018 Nov:37:5-6. doi: 10.1016/j.ebiom.2018.10.073. Epub 2018 Nov 19.

Authors

Martina Petruzzo¹, Marcello Moccia²

Affiliations

¹ Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University, Naples, Italy.
² Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University, Naples, Italy. Electronic address: marcello.moccia@unina.it.

No abstract available

Publication types

Letter

MeSH terms

Animals
Cardiovascular Diseases / etiology*
Cardiovascular Diseases / metabolism
Clinical Trials as Topic
Disease Models, Animal
Humans
Mice, Transgenic
Neuroprotective Agents / adverse effects*
Neuroprotective Agents / pharmacology
Neuroprotective Agents / therapeutic use
Oxidative Stress / drug effects
Uric Acid / adverse effects*
Uric Acid / pharmacology
Uric Acid / therapeutic use

Substances

Neuroprotective Agents
Uric Acid